State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Department of Gastroenterology, The Air Force Hospital From Eastern Theater of PLA, Nanjing, 210002, Jiangsu, China.
Stem Cell Res Ther. 2022 Jul 20;13(1):330. doi: 10.1186/s13287-022-03010-y.
Despite emerging evidence on the therapeutic potential of mesenchymal stem cells (MSCs) for liver fibrosis, the underlying mechanisms remain unclear. At present, MSC-derived exosomes (MSC-EXOs) are widely accepted as crucial messengers for intercellular communication. This study aimed to explore the therapeutic effects of MSC-EXOs on liver fibrosis and identify the mechanisms underlying the action of MSC-EXOs.
Carbon tetrachloride was used to induce a liver fibrosis model, which was intravenously administered with MSCs or MSC-EXOs to assess treatment efficacy. The resulting histopathology, fibrosis degree, inflammation and macrophage polarization were analyzed. RAW264.7 and BMDM cells were used to explore the regulatory effects of MSC-EXOs on macrophage polarization. Then, the critical miRNA mediating the therapeutic effects of MSC-EXOs was screened via RNA sequencing and validated experimentally. Furthermore, the target mRNA and downstream signaling pathways were elucidated by luciferase reporter assay, bioinformatics analysis and western blot.
MSCs alleviated liver fibrosis largely depended on their secreted exosomes, which were visualized to circulate into liver after transplantation. In addition, MSC-EXOs were found to modulate macrophage phenotype to regulate inflammatory microenvironment in liver and repair the injury. Mechanically, RNA-sequencing illustrates that miR-148a, enriched in the MSC-EXOs, targets Kruppel-like factor 6 (KLF6) to suppress pro-inflammatory macrophages and promote anti-inflammatory macrophages by inhibiting the STAT3 pathway. Administration of miR-148a-enriched MSC-EXOs or miR-148a agomir shows potent ameliorative effects on liver fibrosis.
These findings suggest that MSC-EXOs protect against liver fibrosis via delivering miR-148a that regulates intrahepatic macrophage functions through KLF6/STAT3 signaling and provide a potential therapeutic target for liver fibrosis.
尽管间充质干细胞(MSCs)在肝纤维化治疗方面的潜力已经有了新的证据,但潜在机制仍不清楚。目前,MSC 衍生的外泌体(MSC-EXOs)被广泛认为是细胞间通讯的重要信使。本研究旨在探讨 MSC-EXOs 对肝纤维化的治疗作用,并确定 MSC-EXOs 作用的机制。
使用四氯化碳诱导肝纤维化模型,通过静脉注射 MSC 或 MSC-EXOs 来评估治疗效果。分析所得的组织病理学、纤维化程度、炎症和巨噬细胞极化。使用 RAW264.7 和 BMDM 细胞来探索 MSC-EXOs 对巨噬细胞极化的调节作用。然后,通过 RNA 测序筛选出介导 MSC-EXOs 治疗效果的关键 miRNA,并通过实验进行验证。此外,通过荧光素酶报告基因检测、生物信息学分析和 Western blot 阐明了靶 mRNA 和下游信号通路。
MSCs 缓解肝纤维化主要依赖于其分泌的外泌体,这些外泌体在移植后被观察到循环进入肝脏。此外,MSC-EXOs 被发现可以调节巨噬细胞表型,从而调节肝脏中的炎症微环境并修复损伤。从机制上讲,RNA 测序表明,富含 MSC-EXOs 的 miR-148a 通过抑制 STAT3 通路来靶向 Kruppel 样因子 6(KLF6),从而抑制促炎巨噬细胞并促进抗炎巨噬细胞。给予富含 miR-148a 的 MSC-EXOs 或 miR-148a 激动剂可显著改善肝纤维化。
这些发现表明,MSC-EXOs 通过递送 miR-148a 来保护肝脏免受纤维化,miR-148a 通过 KLF6/STAT3 信号通路调节肝内巨噬细胞功能,并为肝纤维化提供了潜在的治疗靶点。